Antagonists of growth hormone-releasing hormone inhibit growth of androgen-independent prostate cancer through inactivation of ERK and Akt kinases

The management of castration-resistant prostate cancer (CRPC) presents a clinical challenge because of limitations in efficacy of current therapies. Novel therapeutic strategies for the treatment of CRPC are needed. Antagonists of hypothalamic growth hormonereleasing hormone (GHRH) inhibit growth of...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Proceedings of the National Academy of Sciences - PNAS 2012-01, Vol.109 (5), p.1655-1660
Hauptverfasser:	Rick, Ferenc G., Schally, Andrew V., Szalontay, Luca, Block, Norman L., Szepeshazi, Karoly, Nadji, Mehrdad, Zarandi, Marta, Hohla, Florian, Buchholz, Stefan, Seitz, Stephan
Format:	Artikel
Sprache:	eng
Schlagworte:	Antagonist drugs antagonists Apoptosis - drug effects Biological Sciences Cancer Cell growth Cell Line, Tumor Cell lines Cell Proliferation Cells Extracellular Signal-Regulated MAP Kinases - antagonists & inhibitors Growth factors Growth Hormone-Releasing Hormone - antagonists & inhibitors Growth hormones growth retardation Heterologous transplantation Hormone antagonists Hormones Humans Inactivation Male mitogen-activated protein kinase Prostate Prostate cancer prostatic neoplasms Prostatic Neoplasms - enzymology Prostatic Neoplasms - pathology Proto-Oncogene Proteins c-akt - antagonists & inhibitors Receptors reverse transcriptase polymerase chain reaction Sermorelin - analogs & derivatives Sermorelin - pharmacology somatoliberin therapeutics Tumors Western blotting
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!